- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Bispecific Antibodies in Multiple Myeloma: Optimizing Care Across Settings
This AJMC Peer Exchange program brings together multiple myeloma experts to discuss the rapidly evolving role of bispecific antibodies across treatment settings. Panelists examine emerging clinical data, real world evidence, safety considerations, and practical strategies for integrating these therapies alongside CAR T-cell therapy and antibody drug conjugates. The discussion also highlights ongoing studies evaluating the potential use of bispecifics earlier in the treatment landscape, as well as opportunities to improve access, optimize sequencing, and support effective transitions between academic and community care.
EP. 1: Unmet Needs and Emerging Therapeutic Advances in Multiple Myeloma
Experts discuss the evolving role of bispecific antibodies in multiple myeloma, highlighting treatment advancements and strategies for optimal patient care.
Watch
EP. 2: Challenges in the Management of Relapsed/Refractory Multiple Myeloma
Experts discuss the critical challenges in accessing innovative treatments for relapsed refractory multiple myeloma, emphasizing equity and education.
Watch
EP. 3: Addressing Therapeutic Gaps in Multiple Myeloma with Bispecific Antibody Therapies
Experts discuss the critical challenges in accessing innovative treatments for relapsed refractory multiple myeloma, emphasizing equity and education.
Watch
EP. 4: Bispecific Antibodies in Multiple Myeloma and Practical Definitions of Lines of Therapy
Explore the transformative potential of bispecific antibodies in multiple myeloma, offering hope for improved patient outcomes and possible cures.
Watch
EP. 5: Mechanisms of Action of Bispecific Antibodies in Multiple Myeloma
Explore the unique mechanisms of bispecific antibodies versus CAR T-cell therapies in treating multiple myeloma and their clinical implications.
Watch
Explore the unique mechanisms of bispecific antibodies and their rapid availability compared to CAR T-cell therapies in cancer treatment.
Watch
EP. 7: Bispecific Antibody Efficacy and Safety in Multiple Myeloma: Updates from ASH 2025
Explore the latest insights on clinical trial data and real-world evidence for innovative cancer therapies, highlighting efficacy and safety.
Watch
EP. 8: Clinical Insights on the Efficacy and Safety of Bispecific Antibodies in Multiple Myeloma
Real-world evidence highlights the effectiveness of teclistamab and elranatamab in treating frail multiple myeloma patients, paving the way for future therapies.
Watch
Explore the promising results of the REDIRECT trial, combining bispecific therapies for treating relapsed/refractory myeloma with high response rates.
Watch
EP. 10: Opportunities for Earlier Initiation of Bispecific Therapies in Multiple Myeloma
Explore the promising results of the REDIRECT trial, combining bispecific therapies for treating relapsed/refractory myeloma with high response rates.
Watch
